MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
18.30
+0.15 (0.83%)
Mar 9, 2026, 1:28 PM EDT - Market open
Company Description
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
The company was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics
| Country | Switzerland |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Jorge da Silva |
Contact Details
Address: Dorfstrasse 29 Zug, 6300 Switzerland | |
| Phone | 41 415108022 |
| Website | moonlaketx.com |
Stock Details
| Ticker Symbol | MLTX |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001821586 |
| CUSIP Number | 61559X104 |
| ISIN Number | KY61559X1045 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kristian Reich M.D., Ph.D. | Co-Founder and Chief Scientific Officer |
| Matthias Bodenstedt | Chief Financial Officer |
| Oliver Daltrop Ph.D. | Chief Operations Officer |
| Carla Bretes | Director of Investor Relations and External Communications |
| Nicolas Mosimann Ph.D. | General Counsel |
| Joana Cortez | Associate Vice-President of Legal and Compliance |
| Tino Anthamatten | Vice President of Marketing, Market Access and Pricing |
| Luciana Marques | Associate Vice-President of Human Resources, People and Culture |
| Nuala Brennan | Chief Clinical Development Officer |
| Roman Akbar-Haase | Chief of Staff to the Executive Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2026 | 10-K | Annual Report |
| Feb 23, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Jan 8, 2026 | 8-K | Current Report |
| Dec 8, 2025 | 144 | Filing |
| Dec 8, 2025 | 144 | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 12, 2025 | SCHEDULE 13G | Filing |
| Nov 10, 2025 | SCHEDULE 13D/A | Filing |
| Nov 5, 2025 | 8-K | Current Report |